Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Asset disposition
Appointed CFO
Quarterly results
Appointed director
CC transcript
CELGENE CORP (CELG) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/10/2020 SC 13G CELGENE CORP reports a 7.5% stake in Sutro Biopharma, Inc.
02/10/2020 SC 13G/A CELGENE CORP reports a 4.2% stake in BeiGene, Ltd.
12/13/2019 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
12/09/2019 S-4 POS Form S-4 POS - Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments:
12/09/2019 S-4 POS Form S-4 POS - Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments:
12/09/2019 S-4 POS Form S-4 POS - Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/09/2019 S-4 POS Form S-4 POS - Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments:
12/02/2019 25 Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities:
11/22/2019 8-K Completion of Acquisition or Disposition of Assets, Material Modifications to Rights of Security Holders, Financial Statement...
11/20/2019 8-K Resignation/termination of a director
Docs: "ARTICLE ONE The name of the corporation is Celgene Corporation . ARTICLE TWO The address of the Corporation’ s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801. The name of its registered agent at such address is The Corporation Trust Company. ARTICLE THREE The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware. ARTICLE FOUR The total number of shares which the Corporation shall have the authority to issue is One Thousand shares, all of which shall be shares of Common Stock, with a par value of $0.01 per share. ARTICLE FIVE The directors shall have the power to adopt, amend or repeal By...",
"BYLAWS OF",
"ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT",
"CELGENE Announces plans to transfer listing of Celgene’ s Contingent value rights following Closing of Acquisition by Bristol-Myers Squibb"
11/20/2019 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
11/18/2019 GN Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019
11/15/2019 425 Form 425 - Prospectuses and communications, business combinations:
10/31/2019 10-Q Quarterly Report for the period ended September 30, 2019
10/31/2019 8-K Quarterly results
08/26/2019 8-K Acquisition/merger/asset purchase announced
Docs: "Asset Purchase Agreement dated August 25, 2019, by and between Celgene Corporation, as seller, and Amgen Inc., as purchaser"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy